Mesoblast (NASDAQ: MESO) reported Q4 EPS of $0.13, $0.20 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $4.2 million.

Mesoblast ended FY16 with cash reserves of US$80.9 million. The Company reduced its annual operating and investing cash outflows by 15% (US$16.4 million) to US$89.7 million for FY16 in comparison with the prior financial year. Additionally, Mesoblast outlined cost-cutting measures to further reduce cash burn by up to US$25 million in the year ended 30 June 2017 (FY17) in order to absorb the incremental costs of the heart failure program.

For earnings history and earnings-related data on Mesoblast (MESO) click here.